# Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose

> **NCT07422285** · PHASE1 · RECRUITING · sponsor: **Amgen** · enrollment: 400 (estimated)

## Conditions studied

- Healthy Participants
- Pharmacokinetics

## Interventions

- **DRUG:** Evolocumab Drug Substance A
- **DRUG:** Evolocumab Drug Substance B

## Key facts

- **NCT ID:** NCT07422285
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-16
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07422285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07422285, "Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07422285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*